Can a Non-Obstructing 1.2 cm Renal Pelvis Stone Without Hydronephrosis Cause Pain?
Yes, a 1.2 cm non-obstructing renal pelvis stone without hydronephrosis can absolutely cause pain, and surgical removal should be offered to patients with moderate to severe pain, as recent high-quality evidence demonstrates significant pain relief and quality of life improvement following stone removal.
Evidence for Pain from Non-Obstructing Stones
The most compelling evidence comes from a 2024 prospective multicenter trial 1 that specifically evaluated patients with nonobstructing calyceal stones up to 10 mm and moderate to severe pain. This study demonstrated:
- Preoperative pain scores: Mean Brief Pain Inventory (BPI) score of 5.5 and worst pain score of 7.2
- 12-week postoperative outcomes: Mean pain dropped to 1.8 and worst pain to 2.8
- Clinical significance: 86% of patients achieved at least 20% pain reduction, and 69% achieved at least 50% pain reduction
- Quality of life: Wisconsin Stone Quality of Life scores increased from 70.4 to 115.3
This directly answers your question—your 1.2 cm stone falls within the size range studied and can definitively cause pain even without obstruction.
Mechanism and Clinical Recognition
While traditional teaching emphasizes that renal colic results from obstruction, the evidence challenges this assumption. A 2008 study 2 found that nonobstructing renal stones are frequently the actual cause of pain in emergency department patients presenting with renal colic symptoms, and these stones are often not recognized by physicians as the pain source, leading to multiple unnecessary evaluations.
Additional supporting evidence from a 2013 study 3 on "small stone syndrome" showed that ureteroscopic treatment of painful, small (≤4 mm) non-obstructing calyceal stones achieved:
- Complete pain resolution in 85% of patients
- Partial pain resolution in 15%
- Improved quality of life in 67%
Clinical Management Algorithm
For Your 1.2 cm Non-Obstructing Renal Pelvis Stone:
If the patient has moderate to severe pain:
- Offer surgical treatment as first-line therapy based on the 2024 prospective trial evidence 1
- Treatment options per 2025 EAU guidelines 4 and 2026 AUA guidelines 5:
- For stones 1-2 cm in the renal pelvis: flexible ureteroscopy (fURS) or shock wave lithotripsy (SWL) are appropriate first-line options
- Mini-PCNL may be offered over URS for 1-2 cm stones when available due to higher stone-free rates 5
If the patient is asymptomatic:
- Active surveillance is acceptable per 2018 guidelines 6, with EAU supporting observation for stones up to 15 mm
- However, close clinical and imaging follow-up is required 7
- Natural history data 8 shows that 28% of asymptomatic stones become symptomatic over 3+ years of follow-up
Important Caveats:
Silent obstruction risk: While rare (3% in one series 8), asymptomatic stones can cause painless silent obstruction. A 2026 case report 9 documented a 24 mm stone causing severe cortical thinning and loss of renal function without any symptoms. This emphasizes the need for imaging follow-up even in asymptomatic patients.
Pain does not correlate with stone size or hydronephrosis: A 2019 study 10 found no correlation between stone size and pain severity, and larger stones were not statistically riskier for hydronephrosis development. This means your 1.2 cm stone can cause significant pain despite the absence of hydronephrosis.
Follow-Up Recommendations
Per 2025 EAU imaging follow-up guidelines 11:
- If treated and stone-free: discharge from imaging follow-up after 2 years for radiopaque stones or 3 years for radiolucent stones
- If residual fragments ≤4 mm: follow-up or repeat intervention based on patient preference
- If fragments >4 mm: repeat intervention recommended due to higher likelihood of symptomatic disease
Bottom Line
Your patient's pain is real and attributable to the stone. The absence of hydronephrosis does not exclude the stone as the pain source. Based on the strongest recent evidence 1, surgical removal should be offered to patients with moderate to severe pain, with expected significant improvement in both pain and quality of life. The choice between fURS, SWL, or mini-PCNL should be based on local expertise, stone characteristics, and shared decision-making with the patient.